Week in Review: Hua Medicine Approved for $200 Million Hong Kong IPO

Deals and Financings

Company News

• Xiangxue Pharma will build a cell-therapy production facility in Guangzhou using GE Healthcare's prefabricated FlexFactory™ system;

Trials and Approvals

• Nanjing Frontier Biotech received CFDA approval for its long-acting HIV treatment and the first China-developed treatment for HIV to be approved for commercialization.

 Stock Symbols: (HK: 3320) (SHA: 600750) (NSDQ: BPMC) (SHE: 300147)

Share this with colleagues:

Original Article: Week in Review: Hua Medicine Approved for $200 Million Hong Kong IPO

More From BioPortfolio on "Week in Review: Hua Medicine Approved for $200 Million Hong Kong IPO"